Other researchers have developed various MRI-targeted nanoprobes for detecting PD-L1 expression in triple-negative breast cancer (Pan et al., 2023; Liu et al., 2023), with similar findings to those in this study. The gene discussed is CD274; the disease is triple-negative breast carcinoma.